Diabetic Neuropathy Market Size, Share, Growth Analysis, By Disorder(Peripheral Neuropathy, Autonomic Neuropathy, Proximal Neuropathy, Focal Neuropathy), By Distribution channel(Hospitals, Clinics, Retail Pharmacy, Online Pharmacy), By Drug Class(Anti-Depressants, Anti-Seizures, Opioid, Non-Steroidal Anti-Inflammatory), By Region - Industry Forecast 2024-2031

Due to the rise in R&D projects, Johnson & Johnson and GlaxoSmithKline plc are the major players outperforming the diabetic neuropathy market. Major market companies are being influenced by this to diversify their product offerings globally. As a result, the important companies' varied product portfolios tend to increase the company's value. For instance, The most significant player in the market is thought to be Pfizer Inc. due to its emphasis on creating goods like Motrin and Lyrica that are expected to fuel growth.

Diabetic Neuropathy Market Top Players Company Profiles

• Johnson & Johnson 
• Pfizer Inc
• Eli Lilly and Company
• Boehringer Ingelheim International GmbH
• GlaxoSmithKline plc
• Astellas Pharma Inc.
• Novartis AG
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• AbbVie Inc.
• Glenmark Pharmaceuticals Limited
• Lupin Pharmaceuticals, Inc.
• Intas Pharmaceuticals Ltd.
• Alkem Laboratories Ltd.
• Cipla Limited
• Mylan N.V.
• Zydus Cadila Healthcare Limited
• Sun Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories Ltd.

Diabetic Neuropathy Market Recent Development

• In January 2022, FDA approved Spinal cord stimulation therapy, according to Medtronic, for the treatment of persistent pain brought on by diabetic peripheral neuropathy.
• In December 2021, in order to develop "Ask your Doctor," the pharma business P&G Health, with its headquarters in India, collaborated with the English-language local newspaper Hindustan Times. The purpose of this online event is to inform the public about diabetic neuropathy and how to treat it.